Re: beefing up PharmaOntology Queries #Q6

Hi Matthias & Eric,

In that case, if could be made generic - rather than finding the specific
interaction between APOE4 and Bapineuzumab , we can retrieve a list of
biomarkers, one of which would be APOE4, that indicate suitability for
treatment with certain drugs, one of which is Bapineuzumab. That way you can
cluster patients according to their biomarkers and assign a treatment per
group. Do you know if that data is available in RDF? If not, is it available
in any other format that can be converted to RDF?

Cheers,
Lena

On Tue, Feb 15, 2011 at 6:09 AM, Matthias Samwald <samwald@gmx.at> wrote:

> Hi Eric,
>
> I'm not an expert, but this seems a bit hard to answer. Bapineuzumb does
> not seem to bind or directly regulate Apolipoprotein and its variants. The
> APOE4 allele is merely a biomarker which can be used to stratify the patient
> population into likely responders and non-responders. Looking at the HCLS
> KB, TMKB and http://lod.openlinksw.com, the (almost) only information that
> can be found about Bapineuzumab are clinical trials from LinkedCT.
> hypothesis.alzforum.org does not have much either, unfortunately.
>
> - Matthias
>
> --------------------------------------------------
> From: "Eric Prud'hommeaux" <eric@w3.org>
> Sent: Monday, February 14, 2011 10:37 PM
> To: <public-semweb-lifesci@w3.org>
> Cc: "Helena Deus" <helenadeus@gmail.com>
> Subject: beefing up PharmaOntology Queries #Q6
>
>
>  Query six¹ matches patients without the APOE4 allel, putatively to
>> match the inclusion criterial for a clinical trial involving
>> Bapineuzumab. Do we have any drug data which links Bapineuzumab to
>> APOE4, so that we query for *any* protein regulated by Beelzebub,
>> rather than specifically APOE4?
>>
>>
>> ¹
>> http://www.w3.org/wiki/HCLSIG/PharmaOntology/Queries#Q6._Are_there_any_AD_patients_without_the_APOE4_allele_as_these_would_be_good_candidates_for_the_clinical_trial_involving_Bapineuzumab.3F
>>
>> --
>> -ericP
>>
>>